Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA4 | P22748 | 1/20 | 0.40 |
| ▸ | CA7 | P43166 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 5/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.37 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2044013 | 0.79 | — | — | |
| SCHEMBL29550002 | 0.74 | AHR (0.48) | GSK3BPDE3BPDE3ABRD4ALDH1A1 | |
| SCHEMBL659375 | 0.74 | AHR (0.48) | GSK3BPDE3BPDE3ABRD4ALDH1A1 | |
| SCHEMBL23272058 | 0.73 | BIRC2 (0.40) | CYP11B1CYP11B2CA12CA1CA2 | |
| SCHEMBL2233893 | 0.73 | NPC1 (0.50) | CYP11B1CYP11B2CYP1A2SMN1; SMN2GSK3B | |
| SCHEMBL30493623 | 0.73 | NPC1 (0.50) | CYP11B1CYP11B2CYP1A2SMN1; SMN2GSK3B | |
| SCHEMBL13629294 | 0.73 | GAA (0.46) | CYP1A2SMN1; SMN2GSK3BALDH1A1ALOX15 | |
| SCHEMBL674111 | 0.72 | CYP11B1 (0.38) | CYP11B1CYP11B2BIRC2PDE3BPDE3A | |
| SCHEMBL3053419 | 0.70 | MAPT (0.53) | CYP11B1CYP11B2CYP1A2SMN1; SMN2GSK3B | |
| SCHEMBL2066798 | 0.70 | CYP11B1 (0.44) | CYP11B1CYP11B2CYP1A2SMN1; SMN2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115515947-A | SHP2 inhibitor and composition and application thereof | 贝达药业股份有限公司 | 2022-12-23 | — | — | CN | claimed |
| EP-0677516-A1 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | claimed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | claimed |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |
| EP-3860990-B1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2022-09-14 | — | — | EP | disclosed |
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | LES LABORATOIRES SERVIER (FR) | 2022-03-31 | — | — | US | disclosed |
| CN-113039182-A | Inhibitors of YAP/TAZ-TEAD interaction and their use in cancer treatment | 伊文蒂瓦公司 | 2021-06-25 | — | — | CN | disclosed |
| EP-3708566-A1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | Galderma Research & Development (FR) | 2020-09-16 | — | — | EP | disclosed |
| EP-2885297-B1 | TRISUBSTITUTED PYRIDO[3,2-D]PYRIMIDINES, THEIR PREPARATION PROCESS AND THEIR THERAPEUTICAL USES | CENTRE NAT DE LA RECH SCIENT (C N R S ) (FR) | 2017-10-11 | — | — | EP | disclosed |
| US-20150190504-A1 | WOUND HEALING | KINETIC CONCEPTS, INC. | 2015-07-09 | — | — | US | disclosed |
| EP-0742216-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1996-11-13 | — | — | EP | disclosed |
| US-5521182-A | ACETYLCHOLINESTERASE INHIBITORS | EISAI CO., LTD. (JP) | 1996-05-28 | — | — | US | disclosed |
| US-5504088-A | ACETYLCHOLINE ESTERASE INHIBITORS; ALZHEIMER'S DISEASE AND OTHER DISEASES CAUSED BY A LOW CONCENTRATION OF CHOLINE | EISAI CO., LTD. (JP) | 1996-04-02 | — | — | US | disclosed |
| EP-0677516-A1 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1995-10-18 | — | — | EP | disclosed |
| US-5292735-A | Cyclic amide derivatives | EISAI CO., LTD. (JP) | 1994-03-08 | — | — | US | disclosed |
| EP-0219923-B1 | ANTIBIOTIC DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-09-02 | — | — | EP | disclosed |
| EP-0468187-A2 | Cyclic amide derivatives | Eisai Co., Ltd. (JP) | 1992-01-29 | — | — | EP | disclosed |
| US-4851422-A | Antibiotic 2-(3-oxo-2-isoxazolidinyl)-5-oxo-2-tetrahydrofuran-carboxylates | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-07-25 | — | — | US | disclosed |
| EP-0219923-A1 | Antibiotic derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | CYP11B1 1866/4885CYP11B2 2152/4885CA12 4740/4885 |
| US-20220098203-A1 | AZA-HETEROBICYCLIC INHIBITORS OF MAT2A AND METHODS OF USE FOR TREATING CANCER | MAT2A, MAT2B, MAT1A | CYP11B1 1747/4885CYP11B2 1107/4885CA12 3262/4885 |
| US-20150190504-A1 | WOUND HEALING | MAPK1, MAPK3, MAPK4 | CYP11B1 2444/4885CYP11B2 2642/4885CA12 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.